9 results
In this research proposal, we aim to investigate for the first time in humans in vivo whether eplerenone promotes adenosine receptor stimulation by activating CD73. The results of these studies will provide a possible explanation for the positive…
The main objectives of this study are:To evaluate the safety and tolerability of three oral dose levels of LTI-291 following 28 days of LTI-291 treatment in patients with GBA-PDTo characterize the plasma and CSF pharmacokinetics (PK) of LTI-291…
- To evaluate the safety and tolerability of four different single oral doses of LTI-291 in healthy subjects.- To characterize the plasma pharmacokinetics (PK) of LTI-291 following single oral dosing in healthy subjects.- To evaluate the…
- To evaluate the safety and tolerability of four oral dose levels of LTI-291 following multiple administrations in healthy middle-aged to elderly subjects. - To characterize the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of LTI-291…
Primary objective of the study is• To investigate efficacy and safety of different oraldoses of BAY94-8862 given once daily over 90 daysThe secondary objectives are:•To assess the effects of these doses on a compositeendpoint of death from any cause…
Primary:- to investigate the safety and tolerability of the study drug after multiple oral dosing in healthy volunteersSecondary:- to investigate the effect of the study drug on potassium clearance upon oral potassium challenge after multiple oral…
To assess the impact of eplerenone on cardiovascularmortality and morbidity in patients with acutemyocardial infarction (STEMI) when initiated withinthe first 24 hours of onset of symptoms (preferablyduring the first 12 hours)To investigate the…
Using the model of lipid-induced insulin resistance we will study the hypothesis that pre-treatment with salsalate (salicylsalicylic acid) blunts the development of lipid-induced insulin resistant in an I*B/NF*B dependent manner in healthy human…
This study is a proof-of-efficacy, dose finding study of LCI699 in patients with mild-to-moderate uncomplicated essential hypertension in order to assess whether the BP effect, safety and tolerability of LCI699 as compared to those of placebo…